A record of what Sandip Sabharwal said publicly, with the source. Not advice.
Pending — not yet graded
“Bullish on the overall pharma universe in the near term, as imminent tariffs on Indian products from the US seem unlikely. The sector shows overall margin improvements and strong sales. However, he acknowledges a small, longer-term risk from potential tariff issues if negotiations fail, which is causing some valuation adjustments.”
Nifty PharmaBullishCalled 17 Feb 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Sandip Sabharwal’s full track record